The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
A few large pharmaceutical companies are investing billions of dollars through multiple collaboration agreements for the R&D for IDO inhibitors. The synergistic effects of IDO inhibitors with chemotherapy together may create a new opportunity for vaccines and immunotherapy. The combination of IDO inhibitors with vaccines can redefine the cancer treatment in coming years if everything goes in the right direction as per the initial results.
Covered in this report
The report covers the present scenario and the growth prospects of the IDO inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's IDO Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Kyowa Hakko Kirin
Key questions answered in this report
How will the market evolve during the forecast period?
What are the major parameters impacting the market?
What are the key market trends?
What are the challenges to market growth?
Who are the key companies in this market space?
Technavio Announces the Publication of its Research Report - IDO Inhibitors - A Pipeline Analysis Report
Technavio recognizes the following companies in the IDO inhibitors: Pfizer, Bristol-Myers Squibb, and Kyowa Hakko Kirin.
Indoleamine-2,3-dioxygenase (IDO) is one of the several immune checkpoints involved in tumor immune escape. It is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along with the kynurenine pathway. By inhibiting IDO, researchers hope to restore immune system responses so that cancer cells can be more easily identified and destroyed.
As most of the IDO inhibitors are currently in the very nascent stage, predicting the future is not sensible at this point of time. However, if it succeeds to enter the market in coming years, then IDO inhibitors may not only transform the way to treat advanced melanoma, but also how the treatment for non-small lung cancer, triple-negative breast cancer, and bladder cancer are being carried out with the existing therapies. Most likely that would be huge news for the researchers and the patients as well.
The global IDO inhibitors market is still to witness its first approval for the various type of solid tumors. The majority of the pipeline molecules are still in pre-clinical stage, a few being in Phase II, and only one candidate made its way to Phase III stage of development so far.
Pfizer, Bristol-Myers Squibb, and Kyowa Hakko Kirin.